Contingent tolerance to carbamazepine: a peripheral-type benzodiazepine mechanism.
Rats were tested for anticonvulsant responsivity to agents active at central and peripheral-type benzodiazepine receptors before and after they were made tolerant to the anticonvulsant effects of carbamazepine on amygdala-kindled seizures. Tolerance to carbamazepine in this paradigm is a contingent process; it occurs when the drug is administered prior to, but not following the kindled seizure. In animals tolerant to carbamazepine, cross-tolerance was observed to the anticonvulsant effects of PK11195, which is active at peripheral-type benzodiazepine receptors, but not to diazepam, which affects central-type benzodiazepine receptors. In animals treated with carbamazepine after the kindled seizure (not tolerant), no alteration in the anticonvulsant effect of PK11195 was observed. These data extend previous biochemical and pharmacological findings suggesting the importance of peripheral-type benzodiazepine receptor mechanisms in the anticonvulsant effects of carbamazepine and suggest a role for this site in the process of contingent tolerance development.
Weiss
S R
SR
Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892.
Post
R M
RM
D000679:Amygdala / Q000187:drug effects; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D002220:Carbamazepine / Q000008:administration & dosage / Q000494:pharmacology*; D004361:Drug Tolerance; D007546:Isoquinolines / Q000494:pharmacology*; D007696:Kindling, Neurologic / Q000187:drug effects; D008297:Male; D011292:Premedication; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects*; D012640:Seizures / Q000139:chemically induced; D013997:Time Factors
D000927:Anticonvulsants; D007546:Isoquinolines; D011963:Receptors, GABA-A; D002220:Carbamazepine; C037850:PK 11195